Kailera Therapeutics Inc. (NASDAQ:KLRA) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China.
Investors focused instead on the treatment’s gastrointestinal side effects, with nausea and vomiting reported at high rates in the obesity study, according to Reuters.
Obesity Trial Meets Primary Endpoint
The company said its Phase 3 HARBOR-1 (obesity/overweight) and OUTSTAND-2 (type 2 diabetes) studies met their primary endpoints.
Kailera is concurrently advancing KAI-7535 in a global Phase 2 trial for obesity or overweight. The trial was initiated in April 2026, with data expected in 2027.
